SCHEDULE 13G/A: Vanguard Group Discloses 4.81% Stake in Immunome Inc. Common Stock

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.81% in Immunome Inc.'s common stock as of December 31, 2024.

Summary

• The Vanguard Group, an investment adviser, has filed an Amendment No. 2 to its Schedule 13G regarding its beneficial ownership in Immunome Inc.
• As of December 31, 2024, Vanguard beneficially owned an aggregate of 3,003,438 shares of Immunome Inc. Common Stock.
• This ownership represents 4.81% of the class of Immunome Inc.'s common stock.
• Vanguard holds no sole voting power, but has shared voting power over 92,435 shares.
• The firm holds sole dispositive power over 2,870,204 shares and shared dispositive power over 133,234 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of Immunome Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the stake is below 5%, it represents a significant holding by a major institutional investor, which can be viewed as a vote of confidence. The passive nature of Vanguard's investment reduces concerns about potential control changes.

Positives

• The continued holding by a major institutional investor like The Vanguard Group may signal long-term confidence in Immunome Inc.'s prospects, as their holdings are typically passive and for investment purposes.
• Vanguard's certification that the shares are held in the ordinary course of business and not for control purposes indicates stability in the ownership structure, reducing concerns about potential activist interventions.

Negatives

• The reported ownership of 4.81% is below the 5% threshold, which means Vanguard is no longer required to file new Schedule 13G reports unless their beneficial ownership exceeds 5% again, potentially reducing transparency on their future stake changes if they remain below this threshold.

Risks

• While Vanguard states its holdings are not for control, significant institutional ownership can still indirectly influence corporate governance through voting on proposals or director elections, even if passive.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding Immunome Inc.'s future financial performance or strategic direction. It solely reports beneficial ownership by The Vanguard Group.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors who acquire more than 5% beneficial ownership of a company's stock, typically in the ordinary course of business and without intent to control. The Vanguard Group is one of the world's largest investment management companies, known for its passive investment strategies, meaning its holdings in companies like Immunome Inc. are generally part of broader index or fund portfolios rather than active strategic investments.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder's stake, which can influence investor perception and potentially liquidity. The passive nature of Vanguard's investment suggests stability in the shareholder base.

Key Dates

Keywords

Immunome Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, Equity Stake